Dramatic response of a braf V600E-mutated primary CNS histiocytic sarcoma to vemurafenib

Neurology

Volumn 83, Issue 16, 2014, Pages 1478-1480

  Idbaih, Ahmed ^a,b,c,d   Mokhtari, Karima ^a,b,c,d   Emile, Jean François ^e   Galanaud, Damien ^e   Belaid, Hayat ^e   Bernard, Simon De ^f   Benameur, Neila ^e   Barlog, Vlad Ciprian ^e   Psimaras, Dimitri ^e   Donadieu, Jean ^g   Carpentier, Catherine ^a,b,c   Martin Duverneuil, Nadine ^e   Haroche, Julien ^e   Feuvret, Loic ^e   Zahr, Noel ^e   Delattre, Jean Yves ^a,b,c,d   Hoang Xuan, Khê ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f SA   (France)

^g ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD163 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; GLUCOSE; PROTEIN S 100; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ASTHENIA; BRAIN HEMATOMA; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER DIAGNOSIS; CASE REPORT; CEREBELLUM; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONSCIOUSNESS DISORDER; CONSULTATION; DRUG TOLERABILITY; DYSGEUSIA; GENE MUTATION; HETEROZYGOTE; HISTIOCYTIC SARCOMA; HUMAN; HYDROCEPHALUS; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LUMBAR PUNCTURE; MALE; MEMORY DISORDER; NECK PAIN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PARESTHESIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; STEREOTACTIC BIOPSY; STEROID THERAPY; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR RECURRENCE; VOMITING; CENTRAL NERVOUS SYSTEM NEOPLASMS; FATALITY; GENETICS; METABOLISM; PATHOLOGY; POINT MUTATION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FATAL OUTCOME; HISTIOCYTIC SARCOMA; HUMANS; INDOLES; MAGNETIC RESONANCE IMAGING; MALE; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84925547021     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000880     Document Type: Note

References (7)

1. Swerdlow SH; International Agency for Research on Cancer, World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, France: International Agency for Research on Cancer; 2008.
2. Bell SL, Hanzely Z, Alakandy LM, Jackson R, Stewart W. Primary meningeal histiocytic sarcoma: a report of two unusual cases. Neuropathol Appl Neurobiol 2012;38: 111-114.
3. Devic P, Androdias-Condemine G, Streichenberger N, et al. Histiocytic sarcoma of the central nervous system: a challenging diagnosis. QJM Mon J Assoc Physicians 2012; 105:77-79.
4. Gill-Samra S, Ng T, Dexter M, et al. Histiocytic sarcoma of the brain. J Clin Neurosci Off J Neurosurg Soc Australas 2012;19:1456-1458.
5. Laviv Y, Zagzag D, Fichman-Horn S, Michowitz S. Primary central nervous system histiocytic sarcoma. Brain Tumor Pathol 2013;30:192-195.
6. Wang J, Li T, Chen H, Liu Q. A case of primary central nervous system histiocytic sarcoma. Clin Neurol Neurosurg 2012;114:1074-1076.
7. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120:2700-2703.